Skip to main content
Erschienen in: Endocrine 3/2013

01.12.2013 | Original Article

Subclinical hypothyroidism is associated with elevated high-sensitive C-reactive protein among adult Taiwanese

verfasst von: Ya-Ting Yu, Chih-Te Ho, Hua-Shai Hsu, Chia-Ing Li, Lance E. Davidson, Chiu-Shong Liu, Tsai-Chung Li, Chuen-Ming Shih, Cheng-Chieh Lin, Wen-Yuan Lin

Erschienen in: Endocrine | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Subjects with subclinical hypothyroidism (SCH) are at increased risk for cardiovascular disease (CVD). High-sensitivity C-reactive protein (hsCRP) is one of the inflammatory markers related to CVD. It is unclear whether inflammation is a mechanistic intermediary between SCH and CVD. We aimed to investigate the association between SCH and hsCRP in a Taiwanese population. A baseline cohort of 2,494 participants over the age of 19 was recruited in Taiwan from 2006 to 2008. SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.61–19.9 mIU/L with normal thyroxine concentrations (a total T4 level of 4.9–12.0 μg/dL). Euthyroidism was defined as a serum TSH level of 0.34–5.60 mIU/L. HsCPR was grouped using quartiles. Multiple logistic and linear regression analyses were used to evaluate the relationship between hsCRP and SCH. After adjusting for gender and betel nut chewing, stepwise multiple logistic regression analyses revealed that hsCRP groups were significantly associated with SCH. Compared to the lowest hsCRP quartile, the adjusted odds ratio of having SCH for hsCRP quartile II, III, and IV were 1.38 (0.48–3.98), 1.48 (0.56–3.96), and 2.59 (1.01–6.67), respectively. The significant increase in odds ratios for SCH in progressive hsCRP quartiles reveals a dose–response effect (p < 0.05). Moreover, stepwise multiple linear regression analyses showed that hsCRP was significantly positively associated with serum TSH level after adjusting for potential confounders. Adult Taiwanese with SCH were associated with elevated hsCRP quartiles.
Literatur
1.
Zurück zum Zitat J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)PubMedCrossRef J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)PubMedCrossRef
2.
Zurück zum Zitat J. Karmisholt, S. Andersen, P. Laurberg, Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. Thyroid 18, 303–308 (2008)PubMedCrossRef J. Karmisholt, S. Andersen, P. Laurberg, Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. Thyroid 18, 303–308 (2008)PubMedCrossRef
3.
Zurück zum Zitat V. Fatourechi, Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin. Proc. 84, 65–71 (2009)PubMedCrossRef V. Fatourechi, Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin. Proc. 84, 65–71 (2009)PubMedCrossRef
4.
Zurück zum Zitat T. Tzotzas, G.E. Krassas, T. Konstantinidis, M. Bougoulia, Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 10, 803–808 (2000)PubMedCrossRef T. Tzotzas, G.E. Krassas, T. Konstantinidis, M. Bougoulia, Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 10, 803–808 (2000)PubMedCrossRef
5.
Zurück zum Zitat H. Gharib, R.M. Tuttle, H.J. Baskin, L.H. Fish, P.A. Singer, M.T. McDermott, Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab. 90, 581–585 (2005). discussion 586-587PubMedCrossRef H. Gharib, R.M. Tuttle, H.J. Baskin, L.H. Fish, P.A. Singer, M.T. McDermott, Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab. 90, 581–585 (2005). discussion 586-587PubMedCrossRef
6.
Zurück zum Zitat A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132, 270–278 (2000)PubMedCrossRef A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132, 270–278 (2000)PubMedCrossRef
7.
Zurück zum Zitat V.N. Valentina, B. Marijan, D. Chedo, K. Branka, Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq. Bras Endocrinol. Metabol. 55, 475–480 (2011)PubMedCrossRef V.N. Valentina, B. Marijan, D. Chedo, K. Branka, Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq. Bras Endocrinol. Metabol. 55, 475–480 (2011)PubMedCrossRef
8.
Zurück zum Zitat B. Biondi, E.A. Palmieri, G. Lombardi, S. Fazio, Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 137, 904–914 (2002)PubMedCrossRef B. Biondi, E.A. Palmieri, G. Lombardi, S. Fazio, Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 137, 904–914 (2002)PubMedCrossRef
9.
Zurück zum Zitat B. Biondi, M. Galderisi, L. Pagano, M. Sidiropulos, M. Pulcrano, D. E. A., S. Ippolito, A. Rossi, O. de Divitiis, G. Lombardi, Endothelial-mediated coronary flow reserve in patients with mild thyroid hormone deficiency. Eur. J. Endocrinol. 161, 323–329 (2009)PubMedCrossRef B. Biondi, M. Galderisi, L. Pagano, M. Sidiropulos, M. Pulcrano, D. E. A., S. Ippolito, A. Rossi, O. de Divitiis, G. Lombardi, Endothelial-mediated coronary flow reserve in patients with mild thyroid hormone deficiency. Eur. J. Endocrinol. 161, 323–329 (2009)PubMedCrossRef
10.
Zurück zum Zitat J. Jiskra, Z. Limanova, M. Antosova, Thyroid diseases, dyslipidemia and cardiovascular risk. Vnitr. Lek. 53, 382–385 (2007)PubMed J. Jiskra, Z. Limanova, M. Antosova, Thyroid diseases, dyslipidemia and cardiovascular risk. Vnitr. Lek. 53, 382–385 (2007)PubMed
11.
Zurück zum Zitat T. Shavdatuashvili, Lipoprotein profile and endothelial function in patients with subclinical and overt hypothyroidism. Georgian Med. News 129, 57–60 (2005)PubMed T. Shavdatuashvili, Lipoprotein profile and endothelial function in patients with subclinical and overt hypothyroidism. Georgian Med. News 129, 57–60 (2005)PubMed
12.
Zurück zum Zitat P.J. Owen, R. Sabit, J.H. Lazarus, Thyroid disease and vascular function. Thyroid 17, 519–524 (2007)PubMedCrossRef P.J. Owen, R. Sabit, J.H. Lazarus, Thyroid disease and vascular function. Thyroid 17, 519–524 (2007)PubMedCrossRef
13.
Zurück zum Zitat E.N. Pearce, In people with subclinical hypothyroidism, TSH level >10 mIU/l may predict increased risk of coronary heart disease and related mortality. Evid. Based Med. 16, 31–32 (2011)PubMedCrossRef E.N. Pearce, In people with subclinical hypothyroidism, TSH level >10 mIU/l may predict increased risk of coronary heart disease and related mortality. Evid. Based Med. 16, 31–32 (2011)PubMedCrossRef
14.
Zurück zum Zitat C. McQuade, M. Skugor, D.M. Brennan, B. Hoar, C. Stevenson, B.J. Hoogwerf, Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid 21, 837–843 (2011)PubMedCrossRef C. McQuade, M. Skugor, D.M. Brennan, B. Hoar, C. Stevenson, B.J. Hoogwerf, Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid 21, 837–843 (2011)PubMedCrossRef
15.
Zurück zum Zitat N. Rodondi, W.P. den Elzen, D.C. Bauer, A.R. Cappola, S. Razvi, J.P. Walsh, B.O. Asvold, G. Iervasi, M. Imaizumi, T.H. Collet, A. Bremner, P. Maisonneuve, J.A. Sgarbi, K.T. Khaw, M.P. Vanderpump, A.B. Newman, J. Cornuz, J.A. Franklyn, R.G. Westendorp, E. Vittinghoff, J. Gussekloo, Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304, 1365–1374 (2010)PubMedCrossRef N. Rodondi, W.P. den Elzen, D.C. Bauer, A.R. Cappola, S. Razvi, J.P. Walsh, B.O. Asvold, G. Iervasi, M. Imaizumi, T.H. Collet, A. Bremner, P. Maisonneuve, J.A. Sgarbi, K.T. Khaw, M.P. Vanderpump, A.B. Newman, J. Cornuz, J.A. Franklyn, R.G. Westendorp, E. Vittinghoff, J. Gussekloo, Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304, 1365–1374 (2010)PubMedCrossRef
16.
Zurück zum Zitat F.Y. Tseng, W.Y. Lin, C.C. Lin, L.T. Lee, T.C. Li, P.K. Sung, K.C. Huang, Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J. Am. Coll. Cardiol. 60, 730–737 (2012)PubMedCrossRef F.Y. Tseng, W.Y. Lin, C.C. Lin, L.T. Lee, T.C. Li, P.K. Sung, K.C. Huang, Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J. Am. Coll. Cardiol. 60, 730–737 (2012)PubMedCrossRef
17.
Zurück zum Zitat G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)PubMedCrossRef G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)PubMedCrossRef
18.
Zurück zum Zitat M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metabol. 85, 2993–3001 (2000)CrossRef M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metabol. 85, 2993–3001 (2000)CrossRef
19.
Zurück zum Zitat S. Razvi, L. Ingoe, G. Keeka, C. Oates, C. McMillan, J.U. Weaver, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metabol. 92, 1715–1723 (2007)CrossRef S. Razvi, L. Ingoe, G. Keeka, C. Oates, C. McMillan, J.U. Weaver, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metabol. 92, 1715–1723 (2007)CrossRef
20.
Zurück zum Zitat K. K. Xu, J., Murphy, S.L., Tejada-Vera, B.: Deaths: final data for 2007. National Vital Statistics Reports. 58, (2010) K. K. Xu, J., Murphy, S.L., Tejada-Vera, B.: Deaths: final data for 2007. National Vital Statistics Reports. 58, (2010)
22.
Zurück zum Zitat P. Jeemon, D. Prabhakaran, L. Ramakrishnan, R. Gupta, F. Ahmed, K. Thankappan, C. Kartha, V. Chaturvedi, K. Reddy, Association of high sensitive C-reactive protein (hsCRP) with established cardiovascular risk factors in the Indian population. Nutr Metab (Lond). 8, 19 (2011)PubMedCrossRef P. Jeemon, D. Prabhakaran, L. Ramakrishnan, R. Gupta, F. Ahmed, K. Thankappan, C. Kartha, V. Chaturvedi, K. Reddy, Association of high sensitive C-reactive protein (hsCRP) with established cardiovascular risk factors in the Indian population. Nutr Metab (Lond). 8, 19 (2011)PubMedCrossRef
23.
Zurück zum Zitat M. Saito, T. Ishimitsu, J. Minami, H. Ono, M. Ohrui, H. Matsuoka, Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167, 73–79 (2003)PubMedCrossRef M. Saito, T. Ishimitsu, J. Minami, H. Ono, M. Ohrui, H. Matsuoka, Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167, 73–79 (2003)PubMedCrossRef
24.
Zurück zum Zitat S. La Vignera, R. Condorelli, E. Vicari, A.E. Calogero, Endothelial dysfunction and subclinical hypothyroidism: a brief review. J. Endocrinol. Invest. 35, 96–103 (2012)PubMed S. La Vignera, R. Condorelli, E. Vicari, A.E. Calogero, Endothelial dysfunction and subclinical hypothyroidism: a brief review. J. Endocrinol. Invest. 35, 96–103 (2012)PubMed
25.
Zurück zum Zitat W.J. Hueston, D.E. King, M.E. Geesey, Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol (Oxf). 63, 582–587 (2005)PubMedCrossRef W.J. Hueston, D.E. King, M.E. Geesey, Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol (Oxf). 63, 582–587 (2005)PubMedCrossRef
26.
27.
Zurück zum Zitat J.J. Haggerty, R.N. Golden, J. Garbutt, C. Pedersen, J.S. Simon, D.L. Evans, C.B. Nemeroff, Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int. J. Psychiatr. Med. 20, 193–208 (1990)CrossRef J.J. Haggerty, R.N. Golden, J. Garbutt, C. Pedersen, J.S. Simon, D.L. Evans, C.B. Nemeroff, Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int. J. Psychiatr. Med. 20, 193–208 (1990)CrossRef
28.
Zurück zum Zitat C.C. Chuang, S.T. Wang, P.W. Wang, M.L. Yu, Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontology 44, 162–167 (1998)PubMedCrossRef C.C. Chuang, S.T. Wang, P.W. Wang, M.L. Yu, Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontology 44, 162–167 (1998)PubMedCrossRef
29.
Zurück zum Zitat A. Tuzcu, M. Bahceci, D. Gokalp, Y. Tuzun, K. Gunes, Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr. J. 52, 89–94 (2005)PubMedCrossRef A. Tuzcu, M. Bahceci, D. Gokalp, Y. Tuzun, K. Gunes, Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr. J. 52, 89–94 (2005)PubMedCrossRef
30.
Zurück zum Zitat M. Christ-Crain, C. Meier, M. Guglielmetti, P.R. Huber, W. Riesen, J.J. Staub, B. Muller, Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 166, 379–386 (2003)PubMedCrossRef M. Christ-Crain, C. Meier, M. Guglielmetti, P.R. Huber, W. Riesen, J.J. Staub, B. Muller, Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 166, 379–386 (2003)PubMedCrossRef
31.
Zurück zum Zitat B.O. Asvold, L.J. Vatten, T.I. Nilsen, T. Bjoro, The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT study. Eur. J. Endocrinol. 156, 181–186 (2007)PubMedCrossRef B.O. Asvold, L.J. Vatten, T.I. Nilsen, T. Bjoro, The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT study. Eur. J. Endocrinol. 156, 181–186 (2007)PubMedCrossRef
32.
Zurück zum Zitat J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’Leary, P.J. Leedman, P. Feddema, V. Michelangeli, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern. Med. 165, 2467–2472 (2005)PubMedCrossRef J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’Leary, P.J. Leedman, P. Feddema, V. Michelangeli, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern. Med. 165, 2467–2472 (2005)PubMedCrossRef
33.
Zurück zum Zitat K. Ashizawa, M. Imaizumi, T. Usa, T. Tominaga, N. Sera, A. Hida, E. Ejima, K. Neriishi, M. Soda, S. Ichimaru, E. Nakashima, S. Fujiwara, R. Maeda, S. Nagataki, K. Eguchi, M. Akahoshi, Metabolic cardiovascular disease risk factors and their clustering in subclinical hypothyroidism. Clin. Endocrinol. (Oxf). 72, 689–695 (2010)PubMedCrossRef K. Ashizawa, M. Imaizumi, T. Usa, T. Tominaga, N. Sera, A. Hida, E. Ejima, K. Neriishi, M. Soda, S. Ichimaru, E. Nakashima, S. Fujiwara, R. Maeda, S. Nagataki, K. Eguchi, M. Akahoshi, Metabolic cardiovascular disease risk factors and their clustering in subclinical hypothyroidism. Clin. Endocrinol. (Oxf). 72, 689–695 (2010)PubMedCrossRef
34.
Zurück zum Zitat A.R. Cappola, L.P. Fried, A.M. Arnold, M.D. Danese, L.H. Kuller, G.L. Burke, R.P. Tracy, P.W. Ladenson, Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295, 1033–1041 (2006)PubMedCrossRef A.R. Cappola, L.P. Fried, A.M. Arnold, M.D. Danese, L.H. Kuller, G.L. Burke, R.P. Tracy, P.W. Ladenson, Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295, 1033–1041 (2006)PubMedCrossRef
35.
Zurück zum Zitat G. Vitale, M. Galderisi, G.A. Lupoli, A. Celentano, I. Pietropaolo, N. Parenti, O. De Divitiis, G. Lupoli, Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J. Clin. Endocrinol. Metabol. 87, 4350–4355 (2002)CrossRef G. Vitale, M. Galderisi, G.A. Lupoli, A. Celentano, I. Pietropaolo, N. Parenti, O. De Divitiis, G. Lupoli, Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J. Clin. Endocrinol. Metabol. 87, 4350–4355 (2002)CrossRef
36.
Zurück zum Zitat A. Haribabu, V.S. Reddy, C. Pallavi, A.R. Bitla, A. Sachan, P. Pullaiah, V. Suresh, P.V. Rao, M.M. Suchitra, Evaluation of protein oxidation and its association with lipid peroxidation and thyrotropin levels in overt and subclinical hypothyroidism. Endocrine. Epub Date: 2012/12/12. doi:10.1007/s12020-12012-19849-y (2012) A. Haribabu, V.S. Reddy, C. Pallavi, A.R. Bitla, A. Sachan, P. Pullaiah, V. Suresh, P.V. Rao, M.M. Suchitra, Evaluation of protein oxidation and its association with lipid peroxidation and thyrotropin levels in overt and subclinical hypothyroidism. Endocrine. Epub Date: 2012/12/12. doi:10.​1007/​s12020-12012-19849-y (2012)
37.
Zurück zum Zitat P.H. Dessein, B.I. Joffe, S. Singh, Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthr. Res. Ther. 7, R634–R643 (2005)CrossRef P.H. Dessein, B.I. Joffe, S. Singh, Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthr. Res. Ther. 7, R634–R643 (2005)CrossRef
38.
Zurück zum Zitat B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29, 76–131 (2008)PubMedCrossRef B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29, 76–131 (2008)PubMedCrossRef
39.
Zurück zum Zitat F. Alibaz Oner, S. Yurdakul, E. Oner, A. Kubat Uzum, M. Erguney, Evaluation of the effect of l-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism. Endocrine 40, 280–284 (2011)PubMedCrossRef F. Alibaz Oner, S. Yurdakul, E. Oner, A. Kubat Uzum, M. Erguney, Evaluation of the effect of l-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism. Endocrine 40, 280–284 (2011)PubMedCrossRef
40.
Zurück zum Zitat F. Montecucco, F. Mach, New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin. Interv. Aging 3, 341–349 (2008)PubMed F. Montecucco, F. Mach, New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin. Interv. Aging 3, 341–349 (2008)PubMed
41.
Zurück zum Zitat P.W. Ladenson, P.A. Singer, K.B. Ain, N. Bagchi, S.T. Bigos, E.G. Levy, S.A. Smith, G.H. Daniels, H.D. Cohen, American Thyroid Association guidelines for detection of thyroid dysfunction. Arch. Intern. Med. 160, 1573–1575 (2000)PubMedCrossRef P.W. Ladenson, P.A. Singer, K.B. Ain, N. Bagchi, S.T. Bigos, E.G. Levy, S.A. Smith, G.H. Daniels, H.D. Cohen, American Thyroid Association guidelines for detection of thyroid dysfunction. Arch. Intern. Med. 160, 1573–1575 (2000)PubMedCrossRef
42.
Zurück zum Zitat M. Helfand, C.C. Redfern, Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann. Intern. Med. 129, 144–158 (1998)PubMedCrossRef M. Helfand, C.C. Redfern, Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann. Intern. Med. 129, 144–158 (1998)PubMedCrossRef
Metadaten
Titel
Subclinical hypothyroidism is associated with elevated high-sensitive C-reactive protein among adult Taiwanese
verfasst von
Ya-Ting Yu
Chih-Te Ho
Hua-Shai Hsu
Chia-Ing Li
Lance E. Davidson
Chiu-Shong Liu
Tsai-Chung Li
Chuen-Ming Shih
Cheng-Chieh Lin
Wen-Yuan Lin
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9915-0

Weitere Artikel der Ausgabe 3/2013

Endocrine 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.